BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30518758)

  • 21. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.
    Williams TM; Hassan GS; Li J; Cohen AW; Medina F; Frank PG; Pestell RG; Di Vizio D; Loda M; Lisanti MP
    J Biol Chem; 2005 Jul; 280(26):25134-45. PubMed ID: 15802273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.
    Huang Z; Wu H; Chuai S; Xu F; Yan F; Englund N; Wang Z; Zhang H; Fang M; Wang Y; Gu J; Zhang M; Yang T; Zhao K; Yu Y; Dai J; Yi W; Zhou S; Li Q; Wu J; Liu J; Wu X; Chan H; Lu C; Atadja P; Li E; Wang Y; Hu M
    Cancer Res; 2013 Oct; 73(20):6277-88. PubMed ID: 23980095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The twist box domain is required for Twist1-induced prostate cancer metastasis.
    Gajula RP; Chettiar ST; Williams RD; Thiyagarajan S; Kato Y; Aziz K; Wang R; Gandhi N; Wild AT; Vesuna F; Ma J; Salih T; Cades J; Fertig E; Biswal S; Burns TF; Chung CH; Rudin CM; Herman JM; Hales RK; Raman V; An SS; Tran PT
    Mol Cancer Res; 2013 Nov; 11(11):1387-400. PubMed ID: 23982216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential.
    Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP
    BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.
    Kothari V; Goodwin JF; Zhao SG; Drake JM; Yin Y; Chang SL; Evans JR; Wilder-Romans K; Gabbara K; Dylgjeri E; Chou J; Sun G; Tomlins SA; Mehra R; Hege K; Filvaroff EH; Schaeffer EM; Karnes RJ; Quigley DA; Rathkopf DE; He HH; Speers C; Spratt DE; Gilbert LA; Ashworth A; Chinnaiyan AM; Raj GV; Knudsen KE; Feng FY
    Clin Cancer Res; 2019 Sep; 25(18):5608-5622. PubMed ID: 31266829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The polycomb group protein EZH2 is involved in progression of prostate cancer.
    Varambally S; Dhanasekaran SM; Zhou M; Barrette TR; Kumar-Sinha C; Sanda MG; Ghosh D; Pienta KJ; Sewalt RG; Otte AP; Rubin MA; Chinnaiyan AM
    Nature; 2002 Oct; 419(6907):624-9. PubMed ID: 12374981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.
    Zhao LH; Li Q; Huang ZJ; Sun MX; Lu JJ; Zhang XH; Li G; Wu F
    Cell Death Dis; 2021 Oct; 12(11):974. PubMed ID: 34671018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
    Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
    Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
    He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
    Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin Elicits Antitumor Effects and Downregulates the Histone Methyltransferase Multiple Myeloma SET Domain (MMSET) in Prostate Cancer Cells.
    White-Al Habeeb NM; Garcia J; Fleshner N; Bapat B
    Prostate; 2016 Dec; 76(16):1507-1518. PubMed ID: 27404348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.
    Pulukuri SM; Gorantla B; Knost JA; Rao JS
    Oncogene; 2009 Aug; 28(31):2829-38. PubMed ID: 19503093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
    Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
    Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
    Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
    J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity.
    Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX
    Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
    Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
    PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.
    Saini S; Majid S; Yamamura S; Tabatabai L; Suh SO; Shahryari V; Chen Y; Deng G; Tanaka Y; Dahiya R
    Clin Cancer Res; 2011 Aug; 17(16):5287-98. PubMed ID: 21159887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
    Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
    Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
    Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
    Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer.
    Han Q; Xie QR; Li F; Cheng Y; Wu T; Zhang Y; Lu X; Wong AST; Sha J; Xia W
    Theranostics; 2021; 11(13):6526-6541. PubMed ID: 33995674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.